Biomedical imaging research opportunities workshop IV: A white paper by Hendee, William R. et al.
Biomedical imaging research opportunities workshop IV: A white paper
William R. Hendeea
Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, Wisconsin 53226
Filip Banovac
Georgetown University Hospital, Washington, DC 20007
Paul L. Carson
The University of Michigan Medical Center, Ann Arbor, Michigan 48109
Ralph A. DeFronzo
University of Texas Health Sciences Center, San Antonio, Texas 78201
William C. Eckelman
Molecular Tracer, LLD, Bethesda, Maryland 20892
Gary D. Fullerton
University of Texas Health Sciences Center, San Antonio, Texas 78201
Steven M. Larson
Memorial Sloan-Kettering Cancer Center, New York, New York 10021
Gordon McLennan
Indiana University, Indianapolis, Indiana 46202
Michael J. Welch
Mallinckrodt Institute, St. Louis, Missouri 63110
Received 26 April 2006; revised 22 June 2006; accepted for publication 12 July 2006;
published 26 January 2007
The Fourth Biomedical Imaging Research Opportunities Workshop BIROW IV was held on
February 24–25, 2006, in North Bethesda, MD. The workshop focused on opportunities for re-
search and development in four areas of imaging: imaging of rodent models; imaging in drug
development; imaging of chronic metabolic disease: diabetes; and image guided intervention in the
fourth dimension-time. These topics were examined by four keynote speakers in plenary sessions
and then discussed in breakout sessions devoted to identifying research opportunities and chal-
lenges in the individual topics. This paper synthesizes these discussions into a strategy for future
research directions in biomedical imaging. © 2007 American Association of Physicists in Medi-
cine. DOI: 10.1118/1.2405838
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The Fourth Biomedical Imaging Research Opportunities
Workshop BIROW IV was held on February 24–25 in
North Bethesda, Maryland. BIROW IV was sponsored by the
Academy of Radiology Research ARR, American Associa-
tion of Physicists in Medicine AAPM, American Institute
for Medical and Biological Engineering AIMBE, Biomedi-
cal Engineering Society BMES, and the Radiological Soci-
ety of North America RSNA. Nineteen other medical im-
aging societies served as participating organizations in the
meeting. The purpose of BIROW IV as of BIROWs I, II and
III, which were held in 2003, 2004, and 20051–3 was to
identify and characterize opportunities for scientific research
and engineering development in biomedical imaging.
BIROW IV focused on four imaging areas that offer a
spectrum of opportunities for scientific research and engi-
neering development:1 Imaging of rodent models;
673 Med. Phys. 34 „2…, February 2007 0094-2405/2007/342 Imaging in drug development;
3 Imaging of chronic metabolic disease: Diabetes;
4 Image-guided intervention in the fourth dimension-time.
Each area was addressed in a plenary session in which four
speakers presented their perspectives on the subject and the
research opportunities and challenges it presents, followed
by audience discussion. Each topic was then the focus of
discussion at one of four simultaneous breakout sessions.
Each breakout session presented a forum for the discussion
of research opportunities in the area from four perspectives
related to the objectives of the Roadmap Program of the
National Institutes of Health NIH.4 These four perspectives
were:
1 Does it deepen understanding of fundamental biology?
2 Does it promote collaboration of multidisciplinary
teams?
3 Does it reshape clinical research and promote discovery?
4 Does it improve people’s health?
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lenges to the realization of the research opportunities. The
four questions for this section of the sessions were:
1 What are the scientific challenges?
2 What are the primary obstacles to development?
3 What are the critical technologies that are lacking?
4 What are the impediments to translating the opportunity
to improved health?
The plenary and breakout sessions yielded a wealth of infor-
mation that has been synthesized and edited into the findings
and recommendations presented in this paper.
IMAGING OF RODENT MODELS
Rodents serve as models of human disease and as test
vehicles for guiding and evaluating novel diagnostic and
therapeutic tools to improve the identification and interven-
tion of disease. Imaging of rodent models provides insight
into the molecular mechanisms of health and disease, and
enables researchers to monitor the evolution of disease over
time and in response to various interventions.5–24
RODENT IMAGING: OPPORTUNITIES
Rodent imaging enables qualitative and quantitative as-
sessment of normal and abnormal biological processes, in-
cluding tissue functions such as apoptosis, senescence, stasis,
dormancy, necrosis, and fibrosis, among others. Imaging en-
ables these processes to be tracked over time without requir-
ing the periodic sacrifice of experimental animals. Develop-
mental abnormalities, for example, can best be evaluated by
imaging temporal changes in the same group of animals over
an extended time period. Further, imaging studies are often
substantially less expensive than those that require the peri-
odic sacrifice of animals. New knowledge in rodent genetics
has enabled the development of genetically-mutated rats with
specific disease characteristics, leading to dramatic growth in
the number of human diseases able to be emulated in rodent
models.
New rodent imaging tools make it possible to research
new questions about fundamental biology. Answers to these
questions often lead to an identified need for new imaging
tools to pursue further what has been learned. That is, the
link between new tools and new applications is an iterative
cycle in which each reinforces the other, thereby advancing
the frontiers of new knowledge in human health and disease
through research with rodents. This research is multidisci-
plinary in nature, involving basic and computer scientists,
engineers, mathematicians, and physicians working together
in the use of rodent imaging tools to acquire new knowledge.
Rodent imaging sits at the crossroads between basic re-
search on rodent models of human disease and the evaluation
of treatment methods for human disease using rodent mod-
els. In many cases rodent imaging is the pathway to under-
standing the linkage between the phenotypic expression of
disease and the underlying genetic cause of the disease. Im-
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covery by enabling longitudinal studies of drug effectiveness
with internal controls.
Rodent imaging methods have the potential to bring new
therapies drugs to market sooner, with reduced develop-
ment costs, by providing more efficient pathways for pre-
clinical evaluation of the therapies. Potential contributions
include: 1 confirmation that the drug is delivered to and
interacts with its intended target; 2 measurement and moni-
toring over time of the pharmacokinetics, targeting effi-
ciency, pharmacodynamics, and biodistribution of the drug;
3 characterization of the target tissue; and 4 identification
of subpopulations of cells within the target that respond dif-
ferently to the drug. Rodent imaging can also reduce the time
and cost associated with evaluating nondrug therapies such
as tumor-ablation techniques, radiation treatments, and ge-
netic manipulation of tissues. Finally, technologies for rodent
imaging can sometimes be adapted for human application.
RODENT IMAGING: CHALLENGES
Rodent imaging research faces several challenges, includ-
ing the need for: improved quantitative tools and procedures;
higher frame rates and throughput; greater contrast, spatial,
and temporal resolution; improved temporal and spatial reg-
istration of physiological and molecular data with images;
higher sensitivity and, in cases where ionizing radiation is
employed, reduced dose; integrated instrumentation to elimi-
nate sequential multi-modality imaging studies that are diffi-
cult and time-consuming; standardized imaging protocols to
facilitate multi-institutional collaboration; fast, simple, and
low-cost rodent imaging systems; enhanced ability to distin-
guish effects of a therapy drug from the effects of the im-
aging technique ionizing radiation, anesthesia procedure, or
contrast agent employed.
There is not a centralized source of interest in and funding
for development of rodent imaging systems. The emphasis at
the NIH on hypothesis-driven research compromises the
competitiveness of funding applications that propose the de-
velopment of new imaging tools and techniques. The Depart-
ment of Energy, a substantial supporter of imaging research
in the past, is gradually phasing out its support of such re-
search. The private sector has made only a modest invest-
ment in rodent imaging systems and research. One sugges-
tion is the co-location of rodent housing and imaging
facilities in selected locations across the country, enabling
investigators to achieve cost- and facility-sharing.
There is an opportunity for further technical development
in several rodent imaging technologies. For example, there is
currently a need for: high frequency ultrasound transducer
arrays that provide simultaneous transmission and reception
of ultrasound signals from tissues; rodent-size x-ray com-
puted tomographic units that provide higher speed and con-
trast resolution than that currently available with rodent CT
systems; more efficient x-ray systems that permit dose reduc-
tion to rodents and a measure of the actual dose delivered to
the detectors and the animals; magnetic resonance imaging
coils for small animal imaging; imaging systems that are fast
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ther evolution of methods such as magnetic resonance imag-
ing and spectroscopy that provide quantitative information
about tissues in addition to images; new imaging methods
that do not employ ionizing radiation, including techniques
such as optical imaging and in vivo optical microscopy; de-
velopment of high-specificity radioactive tracers and contrast
agents for genomic and proteomic targets.
Rodent imaging is a young and immature field. Its contri-
butions to understanding human health and disease and to
improved methods for designing and evaluating diagnostic
and treatment techniques are just beginning to be appreci-
ated. Equipment for rodent imaging is still in its infancy, and
many areas for improvement can be identified. Finally, addi-
tional animal models for human disease are needed, espe-
cially those for diseases other than cancer.
IMAGING IN DRUG DEVELOPMENT
More often than not, the effectiveness of a new drug is
determined by a blinded, randomized, and controlled clinical
trial in which symptoms, survival, and specific surrogate
measures are compared between investigational and control
patient groups. This technique is effective and will probably
not be replaced in the foreseeable future as the final step in
vitro cell culture studies, animal model studies, and human
clinical trials in the approval of a drug for marketing and
production. However, clinical trials are time-consuming, ex-
pensive, and highly inefficient in eliminating drugs that
prove to be ineffective.
If it were effective in separating promising from non-
promising drugs, a preliminary step before clinical trials
would accelerate the process of bringing drugs to market
because financial, personnel, and patient resources could be
devoted to just the promising drugs. Such a step would also
be financially advantageous, because money would not be
spent on clinical trials of drugs that ultimately prove to be
physiologically- or cost-ineffective. The current interest in
imaging methods as a mechanism to accomplish this separa-
tion process reflects an evolution in the understanding of
disease from the level of anatomy, physiology, and histology
to the cellular, molecular, and genetic levels. This evolution
has occurred as a result of knowledge gained through sys-
tems biology. Imaging in drug development promises to re-
sult in smaller, less expensive clinical trials with fewer pa-
tients; earlier go/no go decisions on compounds; faster
regulatory approval; and shorter time-to-market of
drugs.25–37
IMAGING IN DRUG DEVELOPMENT:
OPPORTUNITIES
Sophisticated imaging technologies provide images in
registration with quantitative physiological and functional
data. They can yield spatial, temporal, and distributional in-
formation that may reflect the ability of drugs to concentrate
and effect changes in specific molecular targets. This ap-
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plines and can validate in humans the information gained in
preclinical studies of a drug.
To be useful in drug evaluation studies, imaging data must
be held to the same rigorous standards as all data collected
during clinical trials involving patients. Imaging procedures
should meet agreed-upon standards for image acquisition,
image quality, quantitative measurements, and data analysis.
Further, quality assurance procedures should be instituted for
human observer studies, interpretations, and measurements.
Use of imaging to validate the drug-delivery process and
to evaluate the effectiveness of drugs is a multidisciplinary
effort. Imaging physicists, engineers, bioinformaticians,
computer modelers, pharmacologists, physicians, and statis-
ticians are required to make the process successful. Such a
collaboration requires substantial cross-training and an en-
hanced ability to communicate across disciplines and termi-
nologies. Workshops should be conducted to explore the po-
tential of imaging in drug development, and to identify ways
to enhance interdisciplinary communication and collabora-
tion. Identification of useful biomarkers for the effectiveness
of specific drugs should be a focus of some of these work-
shops.
Imaging in drug development could yield databases of
information used to classify patients according to their re-
sponsiveness to specific drugs. Creation of consortia of aca-
demic, industry, and government representatives interested in
specific problems e.g., imaging protocols, optimum biomar-
kers, targeted agents, quantitative assessment would help
expedite the deployment of imaging methods in drug devel-
opment. These groups could share data for metanalysis di-
rected at determining a drug’s therapeutic and cost-
effectiveness. The shared database should be searchable to
maximize its potential application to future drug develop-
ment.
IMAGING IN DRUG DEVELOPMENT: CHALLENGES
Key surrogate markers must be identified for specific
drugs so that their biodistribution and effectiveness can be
determined. In the field of imaging, appropriate tracers and
contrast agents must be designed to yield data important to
the development and biodistribution of drugs that are effec-
tive in addressing the conditions of patient subpopulations. A
partnership is needed between the pharmaceutical industry
and the scientific community to yield drugs tagged with trac-
ers to reveal the biodistribution of the drugs.
The mechanisms of action of specific drugs should be
better understood at the molecular level, so that the right
drugs can be developed for the right targets and for the right
diseases. Currently there is little sense of urgency to accom-
plish these goals, a situation that must be corrected if drug
development and deployment are to be made more timely
and cost-effective. A networked infrastructure to support col-
laborative efforts to expedite drug development and deploy-
ment would contribute to a greater sense of urgency and
enhanced efficiency in getting effective drugs to market in a
more cost-effective manner. This infrastructure should in-
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cies, especially regulatory agencies responsible for drug ap-
proval.
The usefulness of imaging in drug development depends
on consensus about the instrumentation and data-acquisition
methods to be used; the presence of in-depth quality assur-
ance methods; interpretation by skilled, reliable, and inde-
pendent observers; and validated tools for quantitative mea-
surements.
In the United States, the cost of bringing a new drug to
market is approaching $1 billion, and requires several years
of intense effort. Ways to expedite the approval process and
reduce the cost of drug development would be most welcome
by patients, healthcare providers, and payers. Imaging has
the potential to improve this situation. However, for imaging
to be most effective, the molecular mechanisms of the action
of specific drugs should be better understood so that the right
drugs can be developed for the right targets and for the right
diseases.
IMAGING OF CHRONIC METABOLIC DISEASE:
DIABETES
As effective methods have evolved to prevent and treat
acute and infectious diseases, and as greater numbers of
people are living to older ages, chronic diseases are becom-
ing an increasing health and financial burden to society. Of-
ten these diseases are incurable, but their symptoms and con-
sequences may be ameliorated by treatment. Two examples
of chronic diseases in which biomedical imaging is useful in
monitoring the effectiveness of treatment are asthma and dia-
betes mellitus. The latter is chosen to illustrate this role for
biomedical imaging.
Type 2 diabetes mellitus is a serious health condition that
is increasing dramatically in the United States. Currently, 21
million Americans suffer from diabetes and are at substantial
risk for microvascular complications e.g., eye, kidney, and
nerve damage and macrovascular complications that give
rise to heightened morbidity and mortality from events such
as coronary artery disease, myocardial infarction, stroke,
congestive heart failure, and kidney failure. For example,
25%–40% of patients with congestive heart failure CHF
have type 2 diabetes mellitus. The risk of CHF in diabetic
patients is fourfold than in nondiabetic men and eightfold
than in diabetic women. For diabetics, the lifetime risk of
CHF is one in four, with 50% mortality within 2 years in
symptomatic patients. Type 2 diabetes mellitus is a growing
personal and public health issue that needs improved meth-
ods for prevention, diagnosis, treatment, monitoring, and
follow-up. Imaging offers one highly-promising avenue to
these improvements.
IMAGING OF DIABETES: OPPORTUNITIES
Imaging provides a noninvasive method for studying the
mechanisms and complications of diabetes in humans and in
genetically-created animal models, including the ability to
track diabetes-induced changes in both over time. Imaging
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ing, and expedites better methods of controlling this chronic
disease in humans.
Diabetes assaults the cardiovascular system, and cardio-
vascular imaging is an essential tool for understanding the
biology and etiology of the disease.38–56Imaging of chronic
conditions associated with diabetes includes studies of ath-
erosclerotic plaque formation, changes in fat distribution
e.g., visceral, myocardial, and glycosylation of tendons and
other tissues. Imaging has the potential for early detection of
type 2 diabetes and for monitoring the progression of the
disease and the appearance of major risk factors for throm-
bosis, stenosis, and other complications. Imaging can aid in
delineating vascular function arterial distensibility and en-
dothelial function and in determining the effectiveness of
treatments to stabilize or reverse progressive diabetes-
induced deterioration of the vascular system.
Diabetes is a metabolic disorder that challenges the core
knowledge of chemists, biologists, physicians, and behav-
ioral scientists. Diabetes control and treatment, as well as
reduction of the risk of its serious associated health effects,
require a multidisciplinary team of these individuals, work-
ing with scientists and engineers to improve imaging meth-
ods and with biochemists and pharmacologists to develop
qualitative and quantitative biomarkers to evaluate disease
progression in humans and animals.
Use of imaging to gain an improved understanding of
diabetes could lead to a better model of the disease, with
more explicit biomarkers to evaluate disease progression in
organs and in the peripheral vasculature. Included in this
model would be influences such as age, gender, race, genet-
ics, other chronic conditions, and the potential effects of pre-
vious acute illnesses. A more comprehensive model of dia-
betes, based on improved understanding of the disease and
more useful diabetic animal models, would help reshape
clinical research on diabetes and promote discovery of im-
proved approaches to control and potentially cure type 2 dia-
betes mellitus, a chronic disease that is a major public health
challenge for the nation.
Imaging for the detection of subclinical diabetes in as-
ymptomatic individuals could lead to prevention or delay in
the onset of the debilitating effects of diabetes, speed the
development of new therapies and control measures, and
substantially reduce the risk of life-threatening events asso-
ciated with the disease. Further, imaging might eventually be
used to monitor the progression of the disease and the effec-
tiveness of therapeutic measures designed to slow disease
progression.
IMAGING OF DIABETES: CHALLENGES
Diabetes is a chronic disease that is only incompletely
understood, especially with regard to its cause, its relation-
ship with cardiovascular disease, and the variability of its
consequences in different individuals. Development of quali-
tative and quantitative biomarkers at all disease stages are
needed to use imaging to improve the understanding of dia-
betes, monitor its progression in different organs and the pe-
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ment and control. Imaging methods on all scales, from
molecular to whole animal and human, should be explored
for their usefulness in gaining a firmer understanding of dia-
betes and its devastating effects on people.
Better animal models for diabetes are needed; a consor-
tium similar to the mouse consortium of the National Cancer
Institute would be helpful. On the technology side, improved
imaging instrumentation for monitoring disease progression
in the cardiovascular system is needed, as well as tools for
image integration and analysis.
Understanding diabetes requires knowledge from many
fields, including biochemistry, endocrinology, cardiovascular
physiology, and molecular biology. Physicians who treat pa-
tients with diabetes need a core body of knowledge that en-
compasses all of these fields, making the endocrinology of
diabetes one of the more challenging disciplines of medicine.
Advances in diabetes treatment and management, and ulti-
mately prevention, will require interdisciplinary teams from
several specialties working together to improve the under-
standing of the causes and effects of the disease.
To explore the role of imaging in diabetes management
and treatment, animal models are needed that more closely
simulate diabetes in humans. Improved rodent imaging sys-
tems that provide improved spatial, contrast, and temporal
resolution are also needed, as are standardized validation
tools that facilitate the extrapolation of results in animals to
improved management of diabetes in humans. Human imag-
ing applications need better biomarkers that can be tracked
using radiation doses that are within an acceptable range.
Diabetes should be declared an emerging healthcare crisis
in the United States and several other developed countries.
Open forums should be created for discourse on the problem
that include participants from the medical device industry,
pharmaceutical companies, academics, and federal agencies.
These forums should generate a communications network for
information-sharing about the accuracy and reproducibility
of imaging methods, the improvement of biomarkers and
tracers, and results of efforts to improve the quantifiability of
treatment outcomes and reduce the morbidity of diabetes.
Finally, new scientists should be encouraged to enter the re-
search arena of diabetes, which is a major challenge not only
to afflicted individuals and to the health of the public, but
also to the intellectual ability of scientists to master the mul-
tidisciplinary nature of the required research.
FOUR-DIMENSIONAL IMAGE-GUIDED
INTERVENTION
Image-guided intervention IGI refers to the acquisition
and manipulation of biomedical images to actively guide
medical interventions.57–71 With the exceptions of ultrasound
and x-ray fluoroscopy, biomedical images tend to be static
and therefore provide “snapshots” in time rather than con-
tinuous imaging through time. This limitation creates diffi-
culties for image-guided intervention in regions of the body
where voluntary and involuntary motion is present. Ways to
Medical Physics, Vol. 34, No. 2, February 2007overcome this limitation were the focus of the fourth plenary
session of BIROW IV-Image-Guided Intervention in the
fourth Dimension-Time 4D IGI.72
In this session, a major topic of discussion was the need to
convene a multidisciplinary consensus group to begin the
process of developing standards, sharing data, agreeing on
validation methods, and networking individuals into collabo-
rative research teams focused on 4D IGI. This network of
research teams could work with federal agencies to develop
standardized approaches to 4D IGI that would improve over
time as a result of collaborative research among and across
groups. The research policy division of the Society for In-
terventional Radiology Foundation has initiated the develop-
ment of a consortium of IGI Centers of Excellence.
4D IGI: OPPORTUNITIES
Improved methods are needed to quantify motion e.g.,
respiratory, cardiac, peristalsis, iatrogenic and its impact on
organ deformation and the accuracy of IGI. These methods,
which might include functional and molecular imaging tech-
niques, would lead ultimately to better motion-correction al-
gorithms and to more accurate ways to monitor disease re-
sponse over time. As a consequence, the success or lack
thereof of surgical interventions, radiation therapy, and ab-
lative techniques should be more apparent and therefore
more amenable to improvement.
4D IGI is highly technology-dependent and requires a
multidisciplinary team of scientists, engineers, and physi-
cians for its development and deployment. The need for this
multidisciplinary approach led to a reiteration of the need for
a mechanism to allow submission of research applications
listing co-principal investigators as the individuals respon-
sible for the research.
4D IGI is a rather recent technology, and its rate of de-
velopment often outpaces the clinical validation of any par-
ticular technique. Not infrequently, a new 4D IGI technology
obviates the need for a preceding one. A network of collabo-
rative research teams would help address this challenge in
three ways: expediting the clinical validation of a particular
approach, facilitating collaboration among groups to improve
research, and enhancing communication, so that research
groups working in the field would know what others are
doing.
Development of less invasive, more effective interven-
tions is the ultimate goal of 4D IGI. These interventions
could include individualized and targeted therapies moni-
tored in real-time by molecular imaging techniques, employ-
ing new classes of traceable tools and instruments. Areas of
diseased tissue that are less responsive to therapy may be
identifiable with greater precision in the future, so that they
can be treated through supplemental or alternative methods.
The objective of 4D IGI is safer and less-invasive inter-
ventions that yield greater success, which is ultimately the
removal or healing of diseased tissue without damaging nor-
mal tissue to the degree that the patient’s well-being is com-
promised. Another objective is the development and valida-
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the degree to which patient outcome has been improved and
patient discomfort has been minimized.
4D IGI: CHALLENGES
Several key issues emerged during discussion of the chal-
lenges of 4D IGI. These issues include the need for: contin-
ued evolution of multiparametric imaging that encompasses
anatomic, temporal, and functional information; real-time
tracking of motion and organ deformation; automatic error
identification methods that detect misregistration and “loss of
target;” feedback mechanisms to automatically correct for
misregistration and “loss of target;” improved ergonomics of
interventional suites to accommodate imaging equipment
and improve patient access; reducing or eliminating the ex-
posure of patients to ionizing radiation during 4D IGI tech-
niques; a benchmarking database in the public domain to
facilitate research comparisons and collaboration through the
use of predefined datasets.
4D-IGI is totally dependent on computer-generated data
and images that must be provided as needed in the interven-
tional suite. Consequently, 4D IGI must be an on-line pro-
cess that provides accurate coregistration of data from differ-
ent sources in real time.
New algorithms must be developed that meet this crite-
rion within agreed-upon accuracy limits and time restric-
tions. Biomarkers of successful intervention must be identi-
fied for 4D IGI, that may be different from established end
points. For example, successful treatment of a liver tumor by
radio-frequency ablation can cause a temporary increase in
the tumor diameter, and images of the post-treatment tumor
would lead to the conclusion that the treatment failed accord-
ing to the RECIST Response Evaluation Criteria in Solid
Tumors criteria. The RECIST criteria describe four catego-
ries of response of a tumor to drug therapy: CR complete
response=disappearance of all target lesions; PR partial re-
sponse=30%decrease in the sum of the longest diameter of
target lesions; PD progressive disease=20%increase in the
sum of the longest diameter of target lesions; SD stable
disease=small changes that do not meet the above criteria.
Technologies employed in 4D IGI are expensive, but the
payoff is considerable in safer, less invasive, and more effec-
tive interventions. Fundamental research to improve 4D IGI
is dependent on federal funding and requires the NIH, in
particular, to heighten its receptivity to grant applications
focused on technology development that may not be
hypothesis-driven. In addition, investigators should realize
the potential of research support from investors and industry
as mechanisms to further the development of 4D IGI tech-
nologies.
Validating 4D IGI methods through comparison with con-
ventional therapeutic approaches and with other IGI tech-
niques is essential to deployment of the methods. Dissemi-
nating information about this validation to referring
physicians and to healthcare regulators and payers is neces-
sary to the adoption of 4D IGI methods.
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